Respiratory Updates
🟢 To stay up-to-date on pharmacotherapy and other aspects of respiratory diseases🫁 🟢 Thoracic Research Center🔬 🟢 Tehran University of Medical Sciences🎓
Ko'proq ko'rsatish📈 Telegram kanali Respiratory Updates analitikasi
Respiratory Updates (@respiratoryupdates) Ingliz til segmentidagi kanali faol ishtirokchi. Hozirda hamjamiyat 19 592 obunachidan iborat bo'lib, Tibbiyot toifasida 1 177-o'rinni va Eron mintaqasida 17 234-o'rinni egallagan.
📊 Auditoriya ko‘rsatkichlari va dinamika
невідомо sanasidan buyon loyiha tez o‘sib, 19 592 obunachiga ega bo‘ldi.
06 Sentabr, 2026 dagi oxirgi ma’lumotlarga ko‘ra kanal barqaror faollikka ega. Oxirgi 30 kunda obunachilar soni 492 ga, so‘nggi 24 soatda esa 10 ga o‘zgardi va umumiy qamrov yuqori darajada qolmoqda.
- Tasdiqlash holati: Tasdiqlanmagan
- Jalb etish (ER): Auditoriya o‘rtacha 21.25% darajada jalb etiladi. Nashrdan keyingi dastlabki 24 soatda kontent odatda umumiy obunachilar sonining 5.14% ini tashkil etuvchi reaksiyalarni to‘playdi.
- Post qamrovi: Har bir post o‘rtacha 4 162 marta ko‘riladi; birinchi sutkada odatda 1 007 ta ko‘rish yig‘iladi.
- Reaksiyalar va o‘zaro ta’sir: Auditoriya faol: har bir postga o‘rtacha 11 ta reaksiya keladi.
- Tematik yo‘nalishlar: Kontent patient, guideline, edit, reader, society kabi asosiy mavzularga jamlangan.
📝 Tavsif va kontent siyosati
Muallif resursni shaxsiy fikrni ifoda etish maydoni sifatida ta’riflaydi:
“🟢 To stay up-to-date on pharmacotherapy and other aspects of respiratory diseases🫁
🟢 Thoracic Research Center🔬
🟢 Tehran University of Medical Sciences🎓”
Yuqori yangilanish chastotasi (oxirgi ma’lumot 07 Sentabr, 2026 da olingan) sababli kanal doimo dolzarb va katta qamrovli bo‘lib qoladi. Analitika auditoriya kontent bilan faol hamkorlik qilishini, uni Tibbiyot toifasidagi muhim ta’sir nuqtasiga aylantirishini ko‘rsatadi.
Source: Journal of Allergy and Clinical Immunology: In PracticeTopic: High-dose inhaled steroids after severe asthma flare show no added benefit In a large U.S. retrospective cohort study, stepping up to high-dose inhaled corticosteroids (ICS) after a severe asthma exacerbation did not reduce future exacerbation risk. Among patients on medium-dose ICS, escalation to high-dose was associated with higher annualized exacerbation rates and increased likelihood of another flare. Similar lack of benefit was seen when escalating from low- to high-dose ICS. Findings suggest alternative strategies may be preferable to routine high-dose ICS escalation after exacerbations. Link: https://pubmed.ncbi.nlm.nih.gov/41167528/ @HakimApps_Guideline
